2017 looks to be another hot year in which the future of pharma is molded by a plethora of exciting and impressive technologies within the med-tech space that will keep competition stiff as well as providing new availability for breakthrough initiatives so the the health of consumers will continue to be improved. Bioelectronics is one such venture which hopes to converge biology and electronics in a symbiotic collaboration that can treat illnesses in new ways as well as eliminate drugs which typically have done the heavy lifting in many of these niche areas. Artificial intelligence is another one of the hot areas where big players such as IBM continue to use their deep learning algorithms in order to work out nuances that hinder the health of subsets of the population worldwide. There is a lot to look forward to in the coming year.
GlaxoSmithKline has emerged as one of the leaders in the push for viability of bioelectronics, and 2017 should be no different. Also known as electroceuticals, there is a wide range of potential applications to be pursued. One of the leaders in this space is a small but competent Belgian firm called Nuviant Medical which has received the blessing of GSK through a partnership that will aim to take neurostimulation to the next level. Synapse is attempting deep brain stimulation and clinical trials are already under way to test the feasibility of this technology for various medical issues. Synapse is touted as the thinnest and most implantable neurostimulation system on the market with hopes that it will eventually be able to tackle everything from diabetes to arthritis to cancer.
Neurostimulation is also looking to be a great approach towards chronic pain with at least three doctors across North Carolina already treating patients in order to eliminate the need for long-term pain medication use. Such pharmaceuticals can often have potent side effects, so it is being replaced by the St. Jude Axium Neurostimulator which has been approved by the FDA for dorsal root ganglion (DRG) stimulation. As with the GlaxoSmithKline initiative, this neurostimulation innovation is expanding the amount of treatable patients because many were not candidates for other alleviation measures that were the only ones available in the past.
Healthcare is still all about data and that continues to be proven as we enter the 2017 era. IBM Watson Health continues to push for the collection of patient data and the mapping of it to appropriate medical journals and other forms of research. One great example of this is their partnership with Atrius Health in order to develop a cloud based service that can make healthcare decisions easier and more accurate across the board. It is definitely a better time than ever to join the med-tech revolution and hope is increasing for those with all sorts of illnesses.